Fundamental analysis · SEC EDGAR · TTM through 30/09/2026
REGN · Nasdaq · Healthcare
Fundamental quality
79
out of 100
Regeneron Pharmaceuticals, Inc. grows profitably: it increases revenue at double digits (12.7% a year) without giving up profitability (net margin 28.5%). On fundamental quality it scores 79 out of 100, profiling it as a company with solid fundamentals. Its weakest area is its growth (revenue +12.7%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Regeneron is a biotech known for discovering its own drugs with a highly productive science platform. Its two pillars are ophthalmology (macular degeneration) and, with Sanofi, Dupixent — a blockbuster in inflammatory diseases like atopic dermatitis and asthma.
EPS growth: 7.1% · Revenue growth: 12.7%
Net margin: 28.5% · ROE: 14.4% · ROIC: 12.9%
Net debt/EBITDA: -0.31x · FCF: 22.6%
Source: SEC EDGAR · TTM through 30/09/2026
The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 8,497 | 3,513 | 2,004 | -215 |
| 2021 | 16,072 | 8,075 | 6,529 | -906 |
| 2022 | 12,173 | 4,338 | 4,425 | -1,124 |
| 2023 | 13,117 | 3,954 | 3,875 | -747 |
| 2024 | 14,202 | 4,413 | 3,665 | -504 |
| 2025 | 14,343 | 4,505 | 4,081 | -1,132 |
Between 2020 and 2025, revenue went from $8,497M to $14,343M (+69%) and net income went from $3,513M to $4,505M (+28%). Meanwhile, its margins have narrowed (from 41% to 31%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the nine months ended September 30, 2026, versus the nine months ended September 30, 2025 (SEC filings):
Compared with the previous close (June 30, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
$3.41
per share, yearly
8.2% of earnings
Payout
The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Regeneron Pharmaceuticals, Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Regeneron Pharmaceuticals, Inc. a good company to invest in?
In terms of business quality, Regeneron Pharmaceuticals, Inc. scores 79 out of 100 in our analysis, placing it as a company of high fundamental quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Regeneron Pharmaceuticals, Inc. a profitable company?
Very. Regeneron Pharmaceuticals, Inc. shows a net margin of 28.5% and an ROE of 14.4%, typical of a highly profitable business.
Does Regeneron Pharmaceuticals, Inc. have a lot of debt?
No. Regeneron Pharmaceuticals, Inc. has a net cash position: more cash than debt.
Is Regeneron Pharmaceuticals, Inc. growing?
Its revenue has grown 12.7% annualized in recent years and its earnings per share 7.1%.
Does Regeneron Pharmaceuticals, Inc. generate cash?
Yes. It converts about 22.6% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Teva Pharmaceutical Industries (TEVA) · Davita (DVA) · Henry Schein (HSIC) · Brightspring Health Services (BTSG) · Community Health Systems (CYH) · Hims & Hers Health (HIMS) · see more →
The best Healthcare stocks by our model →
Compare Regeneron Pharmaceuticals, Inc. with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see Regeneron Pharmaceuticals, Inc.'s filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.